HSV-1 Encephalitis in an Elderly Man Receiving Ibrutinib for Waldenstrom’s Macroglobulinemia

Ibrutinib is a major new addition to the therapeutic armamentarium for chronic lymphocytic leukemia, mantle cell lymphoma, Waldenstrom’s macroglobulinemia, and chronic graft versus host disease. Though ibrutinib has proven to be a revolutionary new small molecule agent, and has relatively minimal to...

Full description

Saved in:
Bibliographic Details
Main Author: Mark R. Wallace
Format: Article
Language:English
Published: Wiley 2020-01-01
Series:Case Reports in Infectious Diseases
Online Access:http://dx.doi.org/10.1155/2020/6516037
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832553947553857536
author Mark R. Wallace
author_facet Mark R. Wallace
author_sort Mark R. Wallace
collection DOAJ
description Ibrutinib is a major new addition to the therapeutic armamentarium for chronic lymphocytic leukemia, mantle cell lymphoma, Waldenstrom’s macroglobulinemia, and chronic graft versus host disease. Though ibrutinib has proven to be a revolutionary new small molecule agent, and has relatively minimal toxicity as compared to traditional chemotherapy, infections have emerged as a major complication of therapy. While fungal infections have been the most problematic (including CNS aspergillosis), zoster, hepatitis B reactivation, and chronic hepatitis E have been reported in association with ibrutinib therapy. This report describes a case of herpes encephalitis in an 86-year-old Waldenstrom’s patient receiving ibrutinib and speculates as to whether this late life encephalitis may have been related to ibrutinib.
format Article
id doaj-art-6f1e12cd5cba45edbb5c56c9d6ec7bc7
institution Kabale University
issn 2090-6625
2090-6633
language English
publishDate 2020-01-01
publisher Wiley
record_format Article
series Case Reports in Infectious Diseases
spelling doaj-art-6f1e12cd5cba45edbb5c56c9d6ec7bc72025-02-03T05:52:44ZengWileyCase Reports in Infectious Diseases2090-66252090-66332020-01-01202010.1155/2020/65160376516037HSV-1 Encephalitis in an Elderly Man Receiving Ibrutinib for Waldenstrom’s MacroglobulinemiaMark R. Wallace0Skagit Valley Hospital, 360 Hospital Parkway, My Vernon, WA 98273, USAIbrutinib is a major new addition to the therapeutic armamentarium for chronic lymphocytic leukemia, mantle cell lymphoma, Waldenstrom’s macroglobulinemia, and chronic graft versus host disease. Though ibrutinib has proven to be a revolutionary new small molecule agent, and has relatively minimal toxicity as compared to traditional chemotherapy, infections have emerged as a major complication of therapy. While fungal infections have been the most problematic (including CNS aspergillosis), zoster, hepatitis B reactivation, and chronic hepatitis E have been reported in association with ibrutinib therapy. This report describes a case of herpes encephalitis in an 86-year-old Waldenstrom’s patient receiving ibrutinib and speculates as to whether this late life encephalitis may have been related to ibrutinib.http://dx.doi.org/10.1155/2020/6516037
spellingShingle Mark R. Wallace
HSV-1 Encephalitis in an Elderly Man Receiving Ibrutinib for Waldenstrom’s Macroglobulinemia
Case Reports in Infectious Diseases
title HSV-1 Encephalitis in an Elderly Man Receiving Ibrutinib for Waldenstrom’s Macroglobulinemia
title_full HSV-1 Encephalitis in an Elderly Man Receiving Ibrutinib for Waldenstrom’s Macroglobulinemia
title_fullStr HSV-1 Encephalitis in an Elderly Man Receiving Ibrutinib for Waldenstrom’s Macroglobulinemia
title_full_unstemmed HSV-1 Encephalitis in an Elderly Man Receiving Ibrutinib for Waldenstrom’s Macroglobulinemia
title_short HSV-1 Encephalitis in an Elderly Man Receiving Ibrutinib for Waldenstrom’s Macroglobulinemia
title_sort hsv 1 encephalitis in an elderly man receiving ibrutinib for waldenstrom s macroglobulinemia
url http://dx.doi.org/10.1155/2020/6516037
work_keys_str_mv AT markrwallace hsv1encephalitisinanelderlymanreceivingibrutinibforwaldenstromsmacroglobulinemia